Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 20/20 | 0.54 |
| ▸ | OXTR | P30559 | 7/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.53 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.50 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465038 | 0.95 | AVPR1B (0.60) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL3798738 | 0.92 | AVPR1B (0.55) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL3797263 | 0.91 | AVPR1B (0.46) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL1799908 | 0.91 | AVPR1B (0.47) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL15279963 | 0.91 | AVPR1B (0.44) | AVPR1BOXTRAVPR1AAVPR2 | |
| SCHEMBL3268114 | 0.91 | AVPR1B (0.59) | AVPR1BOXTRAVPR1AAVPR2 | |
| SCHEMBL15279950 | 0.91 | AVPR1B (0.44) | AVPR1BOXTRAVPR1AAVPR2 | |
| SCHEMBL15279946 | 0.91 | AVPR1B (0.45) | AVPR1BOXTRAVPR1AAVPR2 | |
| SCHEMBL1796992 | 0.89 | AVPR1B (0.47) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL27681618 | 0.89 | AVPR1B (0.45) | AVPR1BOXTRAVPR1AAVPR2GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158845-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2015-06-11 | — | — | US | disclosed |
| US-9023854-B2 | 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-05-05 | — | — | US | disclosed |
| EP-2231645-B1 | 5-Halogen-substituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases | ABBOTT GMBH & CO KG (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-20110092516-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG | 2011-04-21 | — | — | US | disclosed |
| EP-2231645-A2 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES | Abbott GmbH & Co. KG (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009071689-A2 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092516-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885OXTR 4/4885AVPR1A 3/4885 |
| US-20150158845-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885OXTR 4/4885AVPR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.